This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mans, D. R.A. Articles by Schwartsmann, G. Search for Related Content PubMed PubMed Citation Articles by Mans, D. R.A. Articles by Schwartsmann, G.

Anti-Cancer Drug Discovery and Development in Brazil: Targeted Plant Collection as a Rational Strategy to Acquire Candidate Anti-Cancer Compounds

Comprehensive Cancer Center (CINCAN); South-American Office for Anti-Cancer Drug Development (SOAD), Lutheran University of Brazil, Canoas, RS, Brazil

Correspondence: Gilberto Schwartsmann, M.D., Ph.D., South American Office for Anti-Cancer Drug Development (SOAD), Hospital de Clínicas de Porto Alegre, sala 399 Rua Ramiro Barcelos 2350, 90035-007 Porto Alegre, RS, Brazil. Telephone/Fax: 55-51-316-8012; e-mail: fsoad{at}hcpa.ufrgs.br and gschwart{at}ez-poa.com.br

Throughout medical history, plant products have been shown to be valuable sources of novel anti-cancer drugs. Examples are the Vinca alkaloids, the taxanes, and the camptothecins, derived from the Madagscan periwinkle plant Catharantus roseus, the Pacific yew Taxus brevifolia, and the Chinese tree Camptotheca acuminata, respectively. For this reason, the South-American Office for Anti-Cancer Drug Development has implemented a large-scale project of acquisition and testing of compounds isolated from South American medicinal plants. The species are selected on the basis of a potentially useful phytochemical composition by consulting ethnopharmacological, chemosystemic, and ecological information. The collected samples are dried and first extracted with an organic solvent, then with distilled water. These crude extracts are evaluated at a concentration of 50 µg/ml for antiproliferative activity against one cell line. Extracts that significantly inhibit the growth of the cells (50%) at relatively low concentrations (50 µg/ml) are submitted to the more comprehensive disease-oriented screen of the U.S. National Cancer Institute. In parallel, these samples are further purified by bioassay-guided purification, involving repeated fractionation by diverse chromatography methods. If the active substance is expected to represent a novel structure, it is identified by appropriate chemical techniques, mechanistic studies are performed with a wide diversity of tumor models and laboratory techniques, and efforts are undertaken for the synthesis of potentially more useful analogs.

Key Words. Drug discovery • Natural products • South America • Compound acquisition • Compound selection

This article has been cited by other articles:

				M. Sun, Z. Estrov, Y. Ji, K. R. Coombes, D. H. Harris, and R. Kurzrock Curcumin (diferuloylmethane) alters the expression profiles of microRNAs in human pancreatic cancer cells Mol. Cancer Ther., March 1, 2008; 7(3): 464 - 473. [Abstract] [Full Text] [PDF]

				G. Schwartsmann Breast Cancer in South America: Challenges to Improve Early Detection and Medical Management of a Public Health Problem J. Clin. Oncol., September 15, 2001; 19(90001): 118s - 124. [Abstract] [Full Text] [PDF]